VULCAN BIOSCIENCES

Vulcan Biosciences commercializes a therapy for treating multiple sclerosis (MS), a debilitating disease of the central nervous system. Using Vulcan Biosciences mass spectrometry platform for drug discovery, the company has discovered two patent-pending lead drug candidates with a strong efficacy signal that suppresses paralysis in the preclinical mouse model of MS, and have novel mechanisms-of-action compared to pre-existing treatments. The company is headquartered in Birmingham Alabama and has the appropriate personnel to develop its MS drugs optimally for FDA trials and obtain the financing required to complete this process.